Skip to content

Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years

A Prospective Randomized Multicenter Evaluation of Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04325789
Enrollment
91
Registered
2020-03-30
Start date
2020-06-29
Completion date
2025-12-30
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Full-thickness Rotator Cuff Tears, Rotator Cuff Tears

Keywords

healing, regenerative medicine, interpositional matrix, synthetic scaffold, full-thickness rotator cuff tear, enthesis regeneration

Brief summary

Randomized controlled trial of patients over the age of 55 treated with and without a nanofiber scaffold during rotator cuff repair.

Detailed description

1. INTRODUCTION This document is a protocol for a human research study. This study is to be conducted according to United States standards of Good Clinical Practice in accordance with applicable Federal regulations and institutional research policies and procedures. Despite numerous advancements in surgical techniques and over 250,000 procedures currently performed annually in the United States, failure of tendon healing following rotator cuff surgery occurs frequently with reports as high as 94%. Nonhealing can lead to persistent pain, poor outcomes, and a significant economic burden to society when revision surgery is required. Several factors have been associated with poor tendon healing with age greater than 60 years shown to be a significant risk factor due to diminishing vascularity at the bone tendon interface where the tear typically originates. While numerous techniques have been devised to improve fixation over the past several decades, very few have been developed to address or enhance the biology at the repair site. Rotium nanofiber is a recent FDA approved scaffold (FDA 510(K) #K183236) that has been shown to improve tendon healing to bone in animal studies. It works to mimic the extracellular matrix and helps concentrates and bind cells at the repair site providing a better organizational structure of the healing tissue. The purpose of the current study is to assess if use of the scaffold significantly improves rotator cuff healing and enhances strength in patients at higher risk of perioperative failure of the repair. 2. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE Rotator cuff tears are a frequent cause of shoulder pain and disability in the elderly population. Typically, when conservative measures fail, surgery is often advised. A successful clinical outcome is felt to be heavily predicated on healing of the tendon to the bone. Despite numerous surgical and technical advancements over the past two decades not all repairs heal, with re-tear, or failure-to-heal, remaining the number one complication associated with rotator cuff surgery. This in turn creates a hefty economic burden on society whereupon surgeries are being performed with poor eventual outcomes and ultimately wasted resources. While reasons for failure are multifactorial, a strong correlation has been associated with advancing age. In an observational study on the natural history of rotator cuff disease, patients younger than 50 years old rarely had rotator cuff tears whereas those greater than 60 had a statistically significant greater incidence of unilateral and bilateral tears. Advancing age is believed to alter and change the intrinsic properties of the tendon leading to stiffness, hypovascularity and overall impairment of the biology of tendon healing. Furthermore, when repairs fail, they typically do so within the first four months of surgery. Means, therefore, to enhance the zone of the repair by increasing the cellularity immediately following surgery may improve the overall healing and lessen failures. Recently, nanofiber scaffolds have demonstrated the ability to mimic the extracellular matrix and help structure, organize, and proliferate cellular material. They do so by working, in essence, like a sponge when incorporated into the repair site, helping to bind, organize, and promote cell migration. This in effect, creates a less haphazard arrangement and induces better organization of healing tissue at the cellular level. Rotium, is an FDA-approved, nonwoven, microfiber matrix composed of PLCL (poly L-lactide-co-caprolactone) and PGL (polyglycolide) that is indicated for use in rotator cuff repair to enhance healing at the bone tendon interface. The implant is inserted under the rotator cuff tendon and placed on top of the greater tuberosity at the time of surgery and typically positioned over a suture. In a recent animal study performed at Colorado State University, a nearly 75% increased strength of repair was demonstrated at twelve weeks in those tendons treated with the graft. This will be the first prospective randomized clinical study in humans assessing for a difference in healing and strength in a population of patients considered at high risk for postoperative failure of the repair. 3. STUDY OBJECTIVES Utilizing a randomized controlled trial, this study seeks to evaluate if there is a difference in post-operative healing, strength, and functional outcomes in patients older than 55 years with rotator cuff tears treated with and without the nanofiber scaffold.

Interventions

DEVICEnanofiber scaffold

Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.

Sponsors

Atreon Orthopedics
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

This is a single blinded study. The patient will be blinded to the treatment group.

Intervention model description

Use of the nanofiber scaffold, in addition to SOC, during the rotator cuff repair is the intervention in this study. Study participants will be randomized into either the treatment or the control group. The control group will undergo routine rotator cuff repair without the scaffold to determine if improved healing is demonstrated with the graft. Group 1 (control) Group 2 (nanofiber scaffold)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 55 and older 2. Able to provide informed consent 3. Primary diagnosis of rotator cuff tear

Exclusion criteria

1. Revision rotator cuff surgery 2. Partial thickness rotator cuff tears 3. Massive (greater than 5cm) rotator cuff tears 4. Patients with current tobacco history

Design outcomes

Primary

MeasureTime frameDescription
Failure of the repair24 monthsTo determine if the use of the nanofiber scaffold changes the occurrence of postoperative rotator cuff repair (RCR) failure in patients older than 55 years

Secondary

MeasureTime frameDescription
Change in shoulder range of motionPreoperative, 6 weeks, 3 months, 6 months, 12 months, 24 months postoperativePatients range of motion including forward flexion, abduction and external rotation will be measured preopertively and postoperatively with a manual goniometer at 6 weeks, 3 months, 6 months, 12 months and 24 months postoperatively to measure for differences.
Change in isometric rotator cuff muscle strength peak forcePreoperative, 3 months, 6 months, 12 months, 24 months postoperativeTo determine if the use of the nanofiber scaffold changes postoperative isometric muscle strength following RCR using a Lafayette muscle dynometer. The contralateral shoulder will be assessed for comparison. Measurements will be recorded in peak force and pounds of force.
Change in patient-reported American Shoulder and Elbow ScoresPreoperative, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months postoperativeTo determine if there is a difference in American Shoulder and Elbow scores of patients with rotator cuff tears treated with and without the nanofiber scaffold measured at preoperative visit, 2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months after surgery.
Change in patient-reported postoperative pain (Visual Analogue Scale - Pain)Preoperative, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months postoperativePatient reported postoperative visual analogue pain (on a scale of 0-10), measured preoperatively and postoperatively will be assessed for a difference. Pain scores will be checked at 2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months after surgery.
Change in patient-reported Single Assessment Numeric Evaluation (SANE) scorePreoperative, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months postoperativePatient reported SANE score (on a scale of 0 to 100%), measured preoperatively and postoperatively will be assessed for a difference; Scores will be checked at 2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months after surgery.
Change in patient-reported Veteran Rand 12 (VR-12) scorePreoperative, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, 24 months postoperativePatient reported VR-12 (Veteran rand) will be compared measured postoperatively will be assessed for a difference; Scores will be checked at 2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months after surgery.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBrian L Badman, MD

Central Indiana Orthopedics

STUDY_DIRECTORElsa I Englund Kayuha, MD

Atreon Orthopedics

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026